GSK stops over 30 research programmes to prioritise innovation
New boss Emma Walmsley outlines sweeping changes in order to focus on high-return drug projects
Priorities are shifting throughout UK pharmaceutical giant GlaxoSmithKline as it closes manufacturing sites and exits research projects in order to boost the prospects of other future drugs.